Liza Laws, Author at Labiotech.eu

News and Trends 27 Jul 2022

SomaLogic acquires DNA nanotechnology company Palamedrix

Colorado-based AI data-driven proteomics technology company SomaLogic has entered into an agreement to acquire Palamedrix, Inc., which is involved in DNA nanotechnology. Palamedrix provides scientific and engineering expertise and miniaturization technology, which SomaLogic intends to leverage as it develops the next generation of the SomaScan assay. Proteomic tool The SomaScan assay is a multiplexed, sensitive, quantitative, […]

July 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

A biopharmaceutical company developing anti-inflammatory therapeutics announced today (July 26) that it is going to submit a request for Emergency Use Authorization (EUA). InflaRx made the announcement after encouraging interactions with the US Food and Drug Administration (FDA) at a recent meeting. The company had requested the meeting to discuss a potential EUA submission regarding […]

July 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Israeli foodtech company develops zero-waste plant protein extraction

A novel, waste-free protein extraction method that completes the sustainability loop through the sustainability practice of upcycling has been created by Acre, Israel-Gavan Technologies, Ltd. The foodtech start-up supports the circular economy by positioning total plant extraction at the core of its operations. Itai Cohen, CEO and co-founder of Gavan, said: “Our new, multistep technological […]

July 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […]

July 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […]

July 25, 2022 - 4 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […]

July 25, 2022 - 4 minutesmins - By Liza Laws

lupus autoimmune disease neutrophil citryll

News and Trends 22 Jul 2022

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […]

July 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

Stroke drug given priority medicine status by European Medicines Agency

A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […]

July 22, 2022 - 2 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 22 Jul 2022

Consortium awarded €4M towards platform for personalized cell therapies

A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […]

July 22, 2022 - 4 minutesmins - By Liza Laws

coronavirus COVID 19 Europe biotech lungs

News and Trends 21 Jul 2022

Additional funding for trial to study drug targeting lung immunity in elderly patients

Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […]

July 21, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

SomaLogic acquires DNA nanotechnology company Palamedrix

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

Israeli foodtech company develops zero-waste plant protein extraction

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

Stroke drug given priority medicine status by European Medicines Agency

Consortium awarded €4M towards platform for personalized cell therapies

Additional funding for trial to study drug targeting lung immunity in elderly patients

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Articles by Liza Laws

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!